Stock Updates

A look at a High Market Cap Stock: Bristol-Myers Squibb Company, BMY

Bristol-Myers Squibb Company, BMY is in the exchange NYSE and its industry is Drug Manufacturers – Major in the sector of Healthcare. Based in USA, Bristol-Myers Squibb Company, BMY  has a market cap of 124916.01. Since its IPO date on the 6/1/1972, Bristol-Myers Squibb Company, BMY performance year to date is 9.96%. Today Bristol-Myers Squibb Company, BMY has gained 0.64%, with a current price of 75.28.

Ownership of the company is 0.10% for insider ownership while institutional ownership is 74.70%. The management of the company have seen the company have a payout ratio of 87.80%. Return of assets are at 9.00%, with return on investment at 4.60%.

In terms of debt levels and profit levels, Bristol-Myers Squibb Company, BMY is seeing a long-term debt/equity of 0.44. While Total debt/equity is 0.45. With a profit margin of 17.00%, this is combined with a gross margin of 76.00%, and operating margin of 21.70%. Bristol-Myers Squibb Company ability to meet debt levels, with a current ratio of 1.6, while the quick ratio is 1.4.

For the last year Bristol-Myers Squibb Company, BMY has seen a EPS growth of -22.30%. A performance for the year of 18.04%. The 52-week high is -2.39%, and the 52-week low is 48.64%. The average volume for Bristol-Myers Squibb Company, BMY is 1377377.

With a target price of 77.5, can Bristol-Myers Squibb Company, BMY reach this target? Looking at the value indicators of Bristol-Myers Squibb Company, BMY. Bristol-Myers Squibb Company has a P/E of 79.91 and a forward P/E of 22.83. Perhaps the more useful indicator than P/E, is PEG which has a value of 3.42. Bristol-Myers Squibb Company also has a P/S and a P/B of 7.39 and 8.38 respectively. For P/cash, Bristol-Myers Squibb Company has a value of 26.86, while it is *TBA for P/free cash flow.

At the current price of 75.28, Bristol-Myers Squibb Company has a dividend yield of 2.03%. We see a return on equity of 19.60%.

Looking more long-term Bristol-Myers Squibb Company, is projected to get an EPS growth for the next five years of 23.34%. In the short-term an EPS growth of 25.56% in the next year is forecasted. This is after a EPS growth of -22.30% for this year and for the last five years a -12.20% growth has been seen.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Peter Clarke

Leave a Comment